join action form

The U.S. Securities and Exchange Commission found that between “September 2013 to March 2014, Lion, through its former Chief Executive Officer, Manish Singh, engaged in a scheme to mislead investors.

Lion Biotechnologies, Inc.

Investigation of Securities Class Action

If you purchased , securities and would like to receive information about our investigation concerning the proposed class action against , please complete the form below.

An attorney from the Pawar Law Group will contact you at no cost to give you information and answer your questions concerning the class action.

Are you a current or former employee of the company?*
Yes No 


+Additional Purchases


+Additional Sales

Please provide any additional comments concerning or your other investments in the box below.